Money raised at a premium which is good but it does seem to suggest that they are going to self-fund the trials on their own. Lepu owning 13% would not help a big pharma unless they can get them on side and at a substantial premium to $0.82.
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025
Week 48 Wrap: ASX flirts with 8,500pts; APRA declines mortgage loan easing; Trump's Bessent tied to Dem donor
